Latest Articles

Publication Date
Abemaciclib Plus Fulvestrant Demonstrates Activity in Advanced Endometrial Cancer - Cancer Therapy Advisor

Abemaciclib Plus Fulvestrant Demonstrates Activity in Advanced Endometrial Cancer Cancer Therapy Advisor

Published: June 11, 2024, 7 a.m.
Weight Loss Drugs, Like Mounjaro, Taken By RHONJ Alum, May Reduce Endometrial Cancer Risk - SurvivorNet

Weight Loss Drugs, Like Mounjaro, Taken By RHONJ Alum, May Reduce Endometrial Cancer Risk SurvivorNet

Published: June 11, 2024, 7 a.m.
Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets - The ASCO Post

Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets The ASCO Post

Published: June 10, 2024, 7 a.m.
Endometriosis increases risks for ovarian, endometrial cancers - Healio

Endometriosis increases risks for ovarian, endometrial cancers Healio

Published: June 7, 2024, 7 a.m.
ASCO Reading Room | Sound Evidence to Treat Smaller, Recurrent Endometrial Cancers With Radiotherapy Alone - Medpage Today

ASCO Reading Room | Sound Evidence to Treat Smaller, Recurrent Endometrial Cancers With Radiotherapy Alone Medpage Today

Published: June 5, 2024, 7 a.m.
Leading Cancer Researchers from NYU Langone’s Perlmutter Cancer Center Present Latest Clinical Findings & Research at ASCO 2024 Annual Conference - NYU Langone Health

Leading Cancer Researchers from NYU Langone’s Perlmutter Cancer Center Present Latest Clinical Findings & Research at ASCO 2024 Annual Conference NYU Langone Health

Published: June 3, 2024, 7 a.m.
Integrating proteomics and explainable artificial intelligence: a comprehensive analysis of protein biomarkers for endometrial cancer diagnosis and prognosis - Frontiers

Integrating proteomics and explainable artificial intelligence: a comprehensive analysis of protein biomarkers for endometrial cancer diagnosis and prognosis Frontiers

Published: June 2, 2024, 7 a.m.
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates - PR Newswire

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire

Published: June 1, 2024, 7 a.m.
Construction and validation of a clinical risk model based on machine learning for screening characteristic factors of lymphovascular space invasion in endometrial cancer - Nature.com

Construction and validation of a clinical risk model based on machine learning for screening characteristic factors of lymphovascular space invasion in endometrial cancer Nature.com

Published: June 1, 2024, 7 a.m.
FDA grants breakthrough designation for ovarian cancer liquid biopsy - TechTarget

FDA grants breakthrough designation for ovarian cancer liquid biopsy TechTarget

Published: May 31, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!